R&D Alzheimer’s: Starting the impossible journey Not long ago, the prospect of having disease-modifying treatments for Alzheimer’s disease (AD) seemed almost a flight of fancy.
News Scenic Bio raises $31m for genetic modifier platform 18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted m
News Novartis taps China's Abogen for autoimmunity TCE Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
